This project focuses on the genetic dissection of the role of DNA mismatch repair deficiency in immune checkpoint inhibitor therapy against glioblastoma in vivo. We aim to identify druggable regulators which may sensitize to immune therapy in glioblastoma. The visual abstract below shows the aims and planned tasks of the work package.
Based on the findings of work package B02 there was a shift in reserach focus for the second funding period. The follow-up project leverages recently established human glioblastoma organoid models to lay the groundwork for future molecularly stratified studies and to dissect the mechanisms of treatment-induced resistance (A08).